Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates

J.K. Simona,b,c, M. Maciel Jr.a,d, E.D. Welda,b, R. Wahida, M.F. Pasettia, W.L. Pickinge, K.L. Kotloffa,b, M.M. Levinea,b, M.B. Szteina,b,*

a Division of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA
b Division of Geographic Medicine, Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
c NanoBio Corporation, Ann Arbor, MI, USA
d ETEC Vaccine Program, Naval Medical Research Center, Silver Spring, MD, USA
e Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, OK, USA

Received 30 November 2010; accepted with revision 1 February 2011

KEYWORDS
Vaccine; Shigella; B cell memory; Immunoglobulin A; IgA; Mucosal immunity

Abstract We studied the induction of antigen-specific IgA memory B cells (Bm) in volunteers who received live attenuated Shigella flexneri 2a vaccines. Subjects ingested a single oral dose of 10^7, 10^8 or 10^9 CFU of S. flexneri 2a with deletions in guaBA (CVD 1204) or in guaBA, set and sen (CVD 1208). Antigen-specific serum and stool antibody responses to LPS and Ipa B were measured on days 0, 7, 14, 28 and 42. IgA Bm cells specific to LPS, Ipa B and total IgA were assessed on days 0 and 28. We show the induction of significant LPS-specific IgA Bm cells in anti-LPS IgA seroreponders. Positive correlations were found between anti-LPS IgA Bm cells and anti-LPS IgA in serum and stool; IgA Bm cell responses to IpaB were also observed. These Bm cell responses are likely play an important role in modulating the magnitude and longevity of the humoral response.

© 2011 Elsevier Inc. All rights reserved.

Abbreviations: ASC, antibody secreting cell; Bm, memory B cells; CD, cluster designation; CDC, Center for Disease Control and Prevention; CVD, Center for Vaccine Development; CFU, colony forming units; CMI, cell-mediated immunity; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-linked immunosorbent spot; Ig, immunoglobulin; IpA, Invasion plasmid antigen; IU, international units; LPS, lipopolysaccharide; mAb, monoclonal antibodies; mL, milliliter; mM, millimolar; NIH, National Institutes of Health; PBMC, peripheral blood mononuclear cells; PBS, phosphate buffered saline; PBST, phosphate buffered saline + 0.05% Tween 20; PCR, polymerase chain reaction; PWM, pokeweed mitogen; cRPML, complete Roswell Park Memorial Institute medium; SAC, Staphylococcus aureus Cowan; SFC, spot forming cells; μg, microgram; μM, micromolar; VTEU, Vaccine and Treatment Evaluation Unit; WHO, World Health Organization.

* Corresponding author at: 685 W. Baltimore Street, Suite 480, Baltimore, MD 21201, USA. Fax: +1 410 706 6205.
E-mail address: mksztein@medicine.umaryland.edu (M.B. Sztein).

1521-6616/$ – see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.clim.2011.02.003
We studied the induction of antigen-specific IgA memory B cells (BM) in volunteers who received live attenuated Shigella flexneri 2a vaccines. Subjects ingested a single oral dose of 10^7, 10^8 or 10^9 CFU of S. flexneri 2a with deletions in guaBA (CVD 1204) or in guaBA, set and sen (CVD 1208). Antigen-specific serum and stool antibody responses to LPS and lpaB were measured on days 0, 7, 14, 28 and 42. IgA BM cells specific to LPS, lpaB and total IgA were assessed on days 0 and 28. We show the induction of significant LPS-specific IgA BM cells in anti-LPS IgA responders. Positive correlations were found between anti-LPS IgA BM cells and anti-LPS IgA in serum and stool; IgA BM cell responses to lpaB were also observed. These BM cell responses are likely play an important role in modulating the magnitude and longevity of the humoral response.
1. Introduction

Shigellosis infections continue to be a major cause of morbidity and mortality among children under 5 years old living in the developing world. Every year, there are 165 million cases of shigellosis worldwide and 14,000 cases reported in the United States; it is estimated that because of underreporting, the number of actual cases may be twenty times higher [1,2]. The increasing prevalence of resistance to multiple antimicrobials is of concern [3] and Shigella is considered a Category B bioterror agent by the CDC [4]. Shigella flexneri is endemic throughout the developing world, and causes more mortality than any other species of Shigella [5]. There is a high demand for a safe and effective oral vaccine, and the WHO has prioritized the development of a well-tolerated vaccine that induces durable immunity against shigellosis [1,6].

By engineering rational deletions in the wild-type S. flexneri 2a strain 2457 T, two vaccine candidates, designated CVD 1204 and CVD 1208, were constructed at the Center for Vaccine Development (CVD). CVD 1204 contains deletions in gusA (encoding a guanosine monophosphate synthase) and gusB (encoding an inositol monophosphate dehydrogenase), which impair the biosynthesis of guanine nucleotides; CVD 1208 has additional deletions of set and sen genes that encode Shigella enterotoxins 1 and 2, respectively. In a Phase 1 trial CVD 1204 was shown to be clearly attenuated compared to its wild type parent (based on comparison with data from multiple previous challenge studies), while CVD 1208 appeared fully attenuated yet immunogenic [7]. Clinical adverse reactions (diarrhea, dysentery and/or fever) occurred in 8 of 23 recipients of CVD 1204 but in only 1 of 21 recipients of CVD 1208 [7].

Putative correlates of protection against shigellosis reported in the literature include serum IgG antibodies against lipopolysaccharide (LPS) O antigen and serotype-specific O antigen peripheral blood IgA antibody secreting cells (ASC) [2,8,9]. Other antibody and cell-mediated immune responses (CMI) against conserved antigens such as invasion plasmid antigens (Ipa) may also play a role in protective immunity [2,10-13]. An optimal vaccine should not only induce enduring systemic and mucosal antibody responses but also allow the host to mount an anamnestic immune response upon subsequent re-exposure to antigen. This response is faster, stronger, and qualitatively better than primary responses and depends on the presence of memory B cells [14]. Following natural Shigella infection, as well as after ingestion of some live attenuated Shigella vaccines, relatively long-term humoral and secondary secretory IgA immune responses to LPS in stool have been described [15]. We have previously demonstrated the induction of IgG B cell responses by live attenuated Shigella vaccines in human volunteers [16]. However, the presence of IgA B cell responses has not been reported. In this study we examined the hypothesis that volunteers who display mucosal and serum antibody responses to CVD 1204 and CVD 1208 live-attenuated oral Shigella vaccines also exhibit IgA B cell responses specific to LPS, IgA and other Shigella antigens.

2. Materials and Methods

2.1. Specimens

46 healthy adult volunteers 18–45 years of age from the Baltimore–Washington area received a single oral dose of S. flexneri 2a ΔgusBA (CVD 1204) or S. flexneri 2a ΔgusAB Δsen-set (CVD 1208) as previously described [7]. Volunteers received 10⁷, 10⁸, or 10⁹ CFU of each vaccine strain or placebo, and sera and stools were collected on days 0, 7, 14, 28, and 42. In addition, peripheral blood mononuclear cells (PBMC) were obtained on days 0 and 28 after oral vaccination. PBMC specimens were cryopreserved and stored in liquid nitrogen until use as previously described [17]. Seroresponsiveness, measured by ELISA [7], was defined as ≥4-fold rise of antigen-specific IgA antibody in serum (seroresponders) and a ≥4-fold rise of antigen-specific IgA/total IgA in stool (mucosal responders) after oral vaccination as compared to pre-vaccination. Adequate specimens were available to assay 13 seroresponders and 11 non-seroresponders; these included subjects immunized with placebo or 10⁷, 10⁸, or 10⁹ CFU of the Shigella strains. For B cell assays, subjects from all three dosage levels cohorts were analyzed. Prior to enrollment, the purpose of the study was explained to the subjects and they passed a written test containing questions regarding the rationale for the study, risks and procedures. Informed consent was obtained from all participants and the study was approved by the UMD Institutional Review Board.

2.2. Antigen Preparation

LPS was purified by the hot aqueous phenol method of Westphal [18]. IpaB, IpaC, IpaD, MxiH, VirG and Yersinia pestis LcrV antigens were purified as recombinant proteins from Escherichia coli. A PCR fragment of viiR encompassing amino acids 68–774 was copied from the vir plasmid of S. flexneri 2457 T by standard PCR. The fragment was ligated into pET22b (Novagen, Madison, WI) and the expression product used to transform E. coli NovaBlue. The resulting plasmid was sequenced and used in the protein expression system. IpaB, VirG and LcrV were purified by standard His tag chromatography and dialyzed into PBS as described previously [19,20]. IpaC and MxiH were solubilized from inclusion bodies with 6 M urea, purified by standard His tag chromatography, and refolded by step dialysis into PBS as previously described [21,22]. IpaB was co-expressed with its cognate chaperone, IpgC, as described previously [22]. The complex was purified by standard His tag chromatography via the His tag fused to the IpgC. IpaB was released from IpgC with 1% octyl-polyoxyethylene.

2.3. Mucosal and Systemic Antibodies

Serum antibodies specific for S. flexneri LPS and IpaB were measured by ELISA as we previously described [7]. Briefly, plates were coated with LPS (5 μg/mL) or IpaB (0.1 μg/mL) and blocked with 10% dried milk in PBS. Samples were evaluated in serial 2-fold dilutions. HRP-labeled goat anti-human Fcα chain (ICN) was used as conjugate and TMB microwell Peroxidase (Kirkegaard & Perry Laboratories, KPL) as substrate. Titers were calculated from linear regression curves as the reciprocal serum dilution that produced an OD of 0.2 above the blank (EU/mL). Total and LPS-specific fecal IgA were also measured by ELISA as previously described [7]. Plates were coated with either α-chain specific anti-human IgA (1 μg/mL; Jackson ImmunoResearch Laboratories) or LPS (10 μg/mL). Stool supernatants were tested in serial 2-fold dilutions. HRP-labeled goat anti-human IgA (Jackson) was used as conjugate and TMB (KPL) as substrate. IgA concentrations were calculated by interpolation into a standard curve of human IgA (Calbiochem). Data are reported as the ratio of LPS-specific/total IgA levels.

2.4. Antibody Secreting Cells

IgA and IgG ASCs specific for S. flexneri LPS and IpaB were detected by ELISPOT as we previously described [7,24]. A positive ASC response was defined as a post-vaccination count at least 3 SD above the mean prevaccination count and at least 8 cells/10⁴ PBMC.

2.5. PBMC Expansion

Expansion of PBMC to measure B cell responses was performed as described by Crotty et al. [23]. Briefly, PBMC specimens were thawed, washed with complete RPMI 1640 containing 100 IU/mL penicillin, 100 μg/mL streptomycin (CelGro, Manassas, VA), 2 mM l-glutamine (Bio-Whittaker,Walkersville, MD), and 10% heat-inactivated fetal bovine
serum (HyClone, Logan, UT), and expanded for 5 days in 6-well plates (1 x 10^6 cells/well) in the presence of 1/100,000 pokeweed mitogen (PWM, kindly provided by Dr. S. Crotty), 6 μg/mL CpG-2006 (Qiagen/Operon, Huntsville, AL), 50 μM 3- Mercaptop-ethanol, and 1/ 10,000 Staphylococcus aureus Cowan (Sigma, St. Louis, MO) in CRPMI (expansion media) in a total volume of 2 mL/well. After 2 days of incubation, cells were fed by replacing 2 mL of CRPMI in each well.

2.6. B Memory Cell Assays

96-Well ELISPOT MAHA (Millepore, Billerica, MA) plates were coated with 5 μg/mL LPS, 0.5 μg/mL of lpaB, lpaC, lpaD, VirG, MxiH or Y. pestis LcrV (as a negative control) or 5 μg/mL of mouse anti-human IgA in PBS and incubated overnight at 4 °C. The plates were then blocked with 1% bovine serum albumin (Sigma) in RPMI for 2 h at 37 °C and 5% CO2, and 10^6 expanded PBMC added per well coated with LPS, lpaB, lpaC, lpaD, VirG, MxiH or LcrV. For total IgA measurements, serial 2-fold dilutions were performed starting at 7500 expanded cells/well down to 234 cells/well. Cells were incubated for 5 h at 37 °C and 5% CO2, washed with PBS and incubated with mouse anti-human pan IgA Biotin Conjugated Antibody (Hybridoma Reagent Laboratory, Baltimore, MD) overnight at 4 °C. Subsequently plates were washed with PBS and labeled with horseradish peroxidase-conjugated avidin D Vector Laboratories, Burlingame, CA) for 1 h at room temperature. The substrate 3-Amino-9 ethylcarbazole C (Calbiochem, La Jolla, CA, USA) was added at 100 μL per well for 20 minutes at room temperature and the reaction was stopped with ddH2O. Final enumeration of specific and total SFC was performed using the Immunospot System 3B Analyzer ELISPOT reader (Cellular Technologies Ltd, Shaker Heights, OH) with aid of the Immunospot software version 4.0 (Cellular Technologies Ltd).

Adequate expansion of Bm cells, assessed by the frequency of total IgA detected by ELISPOT, is critical to the sensitivity and consistency of this method. Thus, specimens which did not reach a minimum cut-off level following expansion (arbitrarily defined as the 10th percentile of the levels reached by all volunteers at any time point: i.e., >8300/10^6 total IgA SFC/10^6 expanded cells) were excluded from further analysis. Statistical analysis was performed on the mean number of SFC in antigen-coated wells minus the mean number of SFC in the negative control wells. The limit of detection of antigen-specific/total expanded cells in our assays was 1 in 100,000 (0.001%). The limit of detection of antigen-specific/total IgA secreting cells in each volunteer was determined by taking into account the maximum number of total IgA SFC for that subject in anti-IgA coated ELISPOT wells. The latter had an acceptable minimum of 0.0005% (i.e., 1 specific SFC in the 8300 total IgA SFC/10^6 expanded cells cut-off).

2.7. Flow Cytometry

Eight volunteers had sufficient PBMC available after expansion pre- and post vaccination to enable flow cytometric measurements. Of these subjects, 3 volunteers were responders by LPS IgA in serum and stool by ELISA and 5 were non responders. Of the 3 LPS responders, 2 were also lpaB responders. Expanded PBMC were washed with 1% PBS in PBS and labeled with fluorochrome-labeled mAbs against the following antigens: (1) CD19-ECF (clone J3.119, Beckman-Coulter, Fullerton, CA), (2) CD20-APC-Cy7 (clone L27, BD Biosciences, San Jose, CA), (3) CD27-APC-A700 (clone 1A4DC27, Beckman-Coulter), (4) IgA-Biotin (clone G20-359, BD Biosciences—subsequently labeled with streptavidin-Pacific Orange (InVitrogen, Carlsbad, CA), (5) IgG-PE-Cy5 (clone G18-145, BD Biosciences), (6) integrin α4/β7/Alexa 647 (the anti-integrin α4/β7/ACT-1 mAb was kindly provided by Dr. W. Newman, PaxVax Inc., San Diego, CA and conjugated to Alexa 647 using an Alexa 647-labeling kit (Molecular probes, Eugene, OR), and (7) CD14-PacBlue (clone TUK4 InVitrogen), CD3-PacBlue (clone UCHT1 BD Biosciences) and Vivid (InVitrogen), which were used to exclude cells staining positively with these mAbs using a "dump" channel gating strategy. Incubation with the mAbs was performed in volumes of 50 μL per tube for 20–30 minutes at 4 °C, washed with 1% FBS in PBS, and fixed in 200 μL of 1% formaldehyde until run. Events were acquired on a MoFlow flow cytometer/cell sorter system (Beamaker-Coutler) and analyzed using WinList 6.0 (Verity Software House, Topsham, ME) software.

2.8. Statistical analysis

Microsoft® Office Excel 2007, GraphPad Prism 5.0, and STATA 9.0 were used for statistical analysis. Our hypotheses were evaluated using non-parametric two-sided tests. Pre- and post-vaccination results were paired. Antigen-specific SFC/10^6 expanded cells were divided by total IgA SFC. The Wilcoxon signed rank test was used to assess continuous pre- to post-vaccination antigen-specific Bm responses. Wilcoxon Rank Sum was used to compare responders to non-responders. Correlations between seroresponse and Bm responses were assessed using Spearman rho test for continuous variables and Fisher's exact test for dichotomous variables. Two-sided p values <0.05 were considered significant.

3. Results

3.1. Evaluation of Total and Specific SFC After Expansion of Bm Cells

Twenty four volunteers who received vaccine had sufficient PBMC pre- and post-vaccination to be included in these studies. Thirteen of the 24 subjects were anti-LPS IgA seroresponders. All 13 seroresponders were also mucosal responders by slgA anti-LPS measured in stool. Three individuals were mucosal responders only with IgA fold increases in anti-LPS total stool IgA without a serum response. Cells from one anti-LPS seroresponder had to be excluded from analysis due to inadequate expansion. LPS-specific Bm cells increased from a median of 7 SFC/10^6 expanded cells pre-vaccination to a median of 53 SFC/10^6 expanded cells 28 days post-vaccination (p=0.005) (Fig. 1). Increases were observed in LPS-specific IgA Bm in 10 out of 12 IgA anti-LPS (83%) seroresponders with adequate expansion. Of 24 vaccinated volunteers who had sufficient PBMC to perform these studies, 7 also displayed an IgA anti-lpaB seroresponse. Mean IgA anti-lpaB Bm cells increased from 4 to 20 SFC/10^6 expanded cells pre- to post-vaccination (p=0.062); 4 out of 7 (57%) IgA lpaB seroresponders manifested an increase in IgA anti-lpaB Bm cells. The median percentages of antigen-specific SFC as a proportion of total IgA SFC showed increases from 0.3% pre-vaccination to 0.20% post-vaccination for LPS (p value =0.005) and 0.03% pre-vaccination to 0.10% post-vaccination for lpaB (p=0.2) among seroresponders (Fig. 1). Individuals who were not seroresponders did not exhibit a statistically significant increase in antigen-specific Bm responses pre- to post-vaccination.

Because of the importance of other proteins in Shigella pathogenesis, e.g., VirG (IcsA), MxiH, lpaB, lpaC and lpaD [26,27], we studied whether immunization with a live oral Shigella vaccine also elicited specific Bm to these antigens. Only sporadic Bm responses were observed to lpaC, lpaD, MxiH, and VirG. No responses were detected against Y. pestis LcrV (negative control).

The frequency of Bm can be quantified as the number of anti-LPS or as anti-lpaB specific IgA per 10^6 expanded PBMC or the % of anti-LPS or anti-lpaB specific IgA divided by the total number of IgA producing cells in expanded PBMC. As can be observed in Fig. 2, highly significant correlations were observed between the two methods of quantification.
To evaluate whether immunization with CVD 1204 or CVD 1208 resulted in changes in the proportion of B cell subsets of defined phenotypes, subsets.

3.2. Correlation of BM Responses with Antibody Responses in Serum and Stool

Mucosal responses to vaccination (i.e., the production of secretory IgA in stool) were observed among 16 out of 24 subjects in this study. Among these 16 subjects, strong correlations were observed when comparing their LPS-specific BM (SFC/10^6 expanded cells) frequencies measured on day 28 with their respective post-vaccination peak seroresponse (Fig. 3A), peak mucosal (stool) IgA response (Fig. 3B), and peak peripheral blood IgA ASC responses (Fig. 3C). Strong correlations were also observed among anti-LPS IgA BM and both mucosal and peripheral anti-LPS IgA responses among the 12 individuals who were seroresponders (data not shown). Of importance, the correlations remain significant when results were analyzed as percentages of specific anti-LPS IgA BM divided by total IgA secreting cells in each volunteer. No significant correlations were observed among antibody levels in serum and stool and peripheral BM cells on day 0 (pre-vaccination, data not shown). Calculations taking into account individual spot sizes (a relative measurement of the amount of antibody produced by each cell) did not change the results. Interestingly, no correlations were observed between the levels of LpaB-specific IgA BM cells and the serum levels of anti-LpaB IgA antibodies or the levels of anti-LpaB ASC in circulation (stool anti-LpaB antibody levels were not measured)(data not shown). Among the vaccine recipients who exhibited a mucosal response, the frequencies of IgA BM cells were better correlated with serum LPS IgA titers (Fig. 3) than with serum LPS IgG (Spearman Rho 0.5, p = 0.05).

3.3. Expression of Gut Homing Molecules in Plasmablasts and BM Following Immunization

To evaluate whether immunization with CVD 1204 or CVD 1208 resulted in changes in the proportion of B cell subsets of defined phenotypes, subsets.

![Graphs showing correlation between antigen-specific IgA BM cell responses and antibody responses in serum and stool.](image-url)

**Figure 1** Antigen-specific IgA BM cell responses. Shown are recipients of 10^7 (triangles), 10^6 (circles) and 10^5 (squares) CFU of CVD 1204 (solid lines) and CVD 1208 (broken lines) who mounted a ≥ 4-fold rise of anti-LPS (n=12) and anti-LpaB (n=7) IgA pre to post vaccination and evidenced appropriate BM expansion in vitro; LPS (a) and LpaB (b) ELISPOT performed on days 0 and 28; comparisons made by Wilcoxon Signed Rank Test for 1204 and 1208 combined. Results are expressed as the % of specific BM SFC per total IgA^+ expanded cell populations; horizontal lines represent the median of the corresponding groups.

**Figure 2** Correlation of antigen-specific BM cells per 10^6 expanded PBMC with antigen-specific BM cells/total IgA BM cell counts. BM cells specific for LPS (a) and LpaB (b) among volunteers who exhibited a mucosal response, the individual spot sizes (a relative measurement of the amount of antibody produced by each cell) did not change the results. Strong correlations were also observed among anti-LPS IgA BM and both mucosal and peripheral anti-LPS IgA responses among the 12 individuals who were seroresponders (data not shown). Of importance, the correlations remain significant when results were analyzed as percentages of specific anti-LPS IgA BM divided by total IgA secreting cells in each volunteer. No significant correlations were observed among antibody levels in serum and stool and peripheral BM cells on day 0 (pre-vaccination, data not shown). Calculations taking into account individual spot sizes (a relative measurement of the amount of antibody produced by each cell) did not change the results. Interestingly, no correlations were observed between the levels of LpaB-specific IgA BM cells and the serum levels of anti-LpaB IgA antibodies or the levels of anti-LpaB ASC in circulation (stool anti-LpaB antibody levels were not measured)(data not shown). Among the vaccine recipients who exhibited a mucosal response, the frequencies of IgA BM cells were better correlated with serum LPS IgA titers (Fig. 3) than with serum LPS IgG (Spearman Rho 0.5, p = 0.05).

PBMC obtained before and after oral vaccination were expanded and stained to examine B cell subsets and expression of the gut homing integrin α_4/β_7 receptor. Cells were sequently gated based on forward versus side scatter ("lymph region") followed by the electronic elimination of doublets, dead cells, CD3^+ T cells and CD14^+ macrophages. The CD19^+ cells co-expressing integrin α_4/β_7 (i.e., with the potential to home to the gut) were then gated and analyzed for their expression of IgG or IgA; each of these cell subsets was further gated based on their expression of CD27 and CD20 to define the CD19^+ integrin α_4/β_7^+ CD27^- CD20^+ (largely BM) and CD19^+ integrin α_4/β_7^+ CD27^- CD20^-/low (largely plasmablasts/plasmocytes) subsets [28,29].

The results from these studies demonstrated an increase in IgA secreting cells post-oral vaccination compared to pre-vaccination among the BM seroresponders. This increase was statistically significant when comparing responders to non-responders by Wilcoxon Rank-Sum in the CD19^+ integrin α_4/β_7^+ IgA^- CD27^- CD20^+ as well as CD19^+ integrin α_4/β_7^- IgA^- CD27^+ CD20^-/low subsets (Fig. 4). No significant differences among responders and non-responders were observed in the percentages of any of the other subsets evaluated (i.e., IgG^- subsets, CD19^+ integrin α_4/β_7^- subsets, CD19^+ integrin α_4/β_7^- CD27^- CD20^- and CD19^+ integrin α_4/β_7^- CD27^- CD20^- subsets).
induction of BM responses is widely accepted to be a major factor in the ability of vaccines to stimulate immunity. However, the precise role of lgA in the immune response has been the subject of much debate. The human colon has a higher proportion of intestinal IgA-secreting cells (slgA) compared to other mucosal surfaces. Humans make more lgA than lgG, lgM, and lgE.

Figure 3 Correlation of anti-LPS B$_B$ cell responses with serum and stool antibodies. Recipients of CVD 1204 and CVD 1208 who mounted a ≥4-fold rise of anti-LPS/total stool slgA pre to post vaccination (mucosal responders) and evidenced appropriate B$_B$ expansion in vitro (n=16) were included in the analysis. Peak serum lgA titers to LPS (a), peak stool lgA specific for LPS divided by total lgA (b), and peak LPS specific lgA ASC (c) were plotted against the number of LPS-specific B$_B$ cells/10$^6$ expanded cells 28 days after immunization; dotted lines represent the 95% confidence interval.

4. Discussion

Immune responses induced locally provide the first line of defense against the many pathogens that invade the human host via mucosal surfaces. Humans make more lgA than lgG, lgM, and lgE combined and allows for active transport of slgA across mucosal epithelia to facilitate antigen exclusion and neutralization [30]. The normal human colon has a higher proportion of lgA than lgG-producing plasma cells as evidenced by immunohistochemistry [31]. The induction of B$_B$ responses is widely accepted to be a major factor in the ability of vaccines to elicit long lasting, effective immunity. However, the precise role of lgA ASC and B$_B$ cells in primary and secondary (anamnestic) immune responses to infection remains ill defined.

A B$_B$ response can be demonstrated by documenting: (1) an anamnestic secondary antibody response, both stronger and faster than the initial immune response, (2) avidity maturation, and (3) the presence of B$_B$ cells [32]. B$_B$ cells have been described in humans against vaccines known to induce a T-cell dependent response, including live viral vaccines administered parenterally (e.g., smallpox vaccine [33]) and orally (e.g., rotavirus vaccines [34]) and parenteral conjugate vaccines consisting of bacterial polysaccharides (such as pneumococcal [35] and meningococcal [36] capsular polysaccharides) covalently linked to carrier proteins. B$_B$ cells have also been reported following natural infection with bacterial enteropathogens and after the administration of live oral bacterial enteric vaccines [16,37]. Here we report the observation that oral immunization with attenuated S. flexneri 2a vaccines elicits the generation specific lgA B$_B$ cells.

Although the immunological correlates of protection following Shigella infection have not yet been fully elucidated, high numbers of antigen-specific lgA ASC post oral vaccination have been found to be associated with protection from shigellosis after experimental challenge [8]. Interestingly, the volunteers who have high numbers of antigen-specific ASC after vaccination and are asymptomatic after challenge have low levels of antigen-specific lgA ASC in peripheral blood after secondary antigen exposure [38]. In the present study we observed that a single oral immunization with live attenuated Shigella vaccine CVD 1204 or CVD 1208 elicited significant increases in antigen-specific lgA anti-LPS B$_B$ responses among subjects who mounted ≥fourfold specific slgA or lgA antibody responses as measured by ELISA, respectively, in stool and serum. LpaB seroresponders also exhibited antigen-specific IgA B$_B$ responses to LpaB. Strong correlations were observed between the magnitude of IgA anti-LPS B$_B$ cells and increases in anti-LPS IgA responses, both among individuals who displayed a strong mucosal slgA stool response and among IgA seroresponders. B$_B$ cells also correlated highly with anti-LPS IgA ASC, both among seroresponders and mucosal responders. It will be important to determine in future experimental challenge studies with wild-type Shigella whether antigen-specific lgA and lgG B$_B$ cells are elevated in subjects who had been (or not) previously immunized with oral live attenuated Shigella strains and whether B$_B$ cells are associated with protection.

We were surprised that no differences were detected in the magnitude of B$_B$ cell responses among recipients of the slightly reactogenic CVD 1204 or the very well tolerated CVD 1208, or related to the various dosage levels evaluated (10$^7$, 10$^8$, or 10$^9$ CFU). An optimistic interpretation of this observation is that the loss of reactogenicity resulting in a well tolerated further attenuated Shigella vaccine strains such as strain CVD 1208 is not accompanied by a diminution of the ability to elicit strong immune responses, including the generation of antigen-specific lgA B$_B$ cells.

In previous studies we determined by flow cytometry the proportions of phenotypically defined total B, B$_B$, and IgG$^+$ B$_B$ cell populations before and after expansion [16]. This information helped validate the B$_B$ cell ELISPOT assay as well as provide the rationale for limiting the analyses to specimens that showed evidence of appropriate in vitro expansion in the presence of mitogens. By eliminating specimens that exhibited suboptimal expansion of functional cells (defined as ≤8,300 total IgA SFC/10$^6$ expanded cells) in the current dataset, we observed increased levels of circulating antigen-specific IgA responses elicited by a single oral vaccination of up to 1.1% antigen-specific B$_B$/total IgA SFC post-vaccination for T-independent antigen LPS and up to 1.0% for the T-dependent antigen LpaB. These proportions of antigen-specific B$_B$ cells are similar to those previously reported in subjects who received efficacious parenteral vaccines. For example, responses to diphtheria and tetanus toxoids elicited specific B$_B$ cells over total IgG secreting cells in the range of 0.01–1% [39]. Recombinant hepatitis B vaccine showed the induction of 0.07% hepatitis B surface
antigen-specific Ig secreting cells over total Ig secreting cells; 88% of vaccinees had detectable levels of IgG BM cells and 76% had detectable levels of IgA and IgM BM cells [40]. In natural cholera infection, anti-LPS IgA BM cells have been reported to be 0.6% of total IgA BM cells and proposed to play an important role in the anamnestic mucosal immune response [37]. To our knowledge, the data included in the present manuscript is the first description of the induction of specific IgA BM cell response to LPS in recipients of an oral live-attenuated bacterial vaccine.

Since *Shigella* enters the host via the gut, it is important to define the local immune responses elicited by immunization. Due to regulatory constraints and other factors, intestinal mucosal biopsies are very difficult to obtain following vaccine administration or challenge with wild-type organisms. Alternative ways to investigate whether antigen-specific IgA and IgG ASC and BM found to be elevated in the periphery after oral vaccination have the potential to migrate to the gut mucosa involve indirect measurements, such as SlgA in stool and the measurement of gut homing molecule expression, e.g., integrin α4/β7, on IgA and IgG* ASC and BM cells. Although in our experience flow cytometry is not as sensitive as ELISPOT in assessing antigen-specific BM responses, it nevertheless allowed us to characterize the phenotype of the B cell subsets that increased following oral vaccination.

In the present study we found significant increases in the proportion of vaccine-induced CD19+CD27+CD20+ integrin α4/β7+ IgA* BM cells with a gut homing pattern in seroresponders as compared to non-seroresponders. Smaller, yet significant, increases have also been observed in CD19+CD27+CD20+ integrin α4/β7+ IgA* cells (a phenotype typically associated with plasmablasts)[29]. While BM only express surface Ig, expression of Ig in plasmablasts is largely cytoplasmic with lower levels of surface Ig expression [41]. Because this manuscript is focused on BM and sufficient cells were not available for independent staining panels (i.e., extracellular and intracellular IgA and/or IgG staining), we stained extracellularly for Ig. Thus, it is likely that the smaller differences observed in integrin α4/β7+ IgA* plasmablasts in responders as compared to non-responders are the result of a lower efficiency in the detection of IgG* and IgA* plasmablasts. Future studies using intracellular Ig staining will allow this issue to be addressed directly. In contrast to the increases in IgA* cells, this phenomenon was not observed in CD19+ integrin α4/β7+ IgG BM cells (irrespective of expression of CD27 and/or CD20). In sum, we found that IgA*, but not IgG*, CD19+ BM cells expressing the gut homing receptor integrin α4/β7+ increased 28 days after oral vaccination, and that gating on subsets based on the expression of CD27 and CD20 enhanced the ability to identify this population. This observation is consistent with Crotty’s original description of the BM cell ELISPOT where sorting experiments were used to identify that BM have a CD27*CD20* phenotype [25]. The present results suggest an increase in circulating *Shigella* specific IgA BM and plasmablasts with gut homing potential in individuals in whom immunization elicited anti-*Shigella* humoral responses.

A limitation of this study is the relatively small number of volunteers who could be evaluated; which is largely due to the fact that it employed "convenience" specimens based on availability. In spite of this limitation, we observed strong, statistically significant, specific anti-LPS IgA BM responses and associations with anti-LPS IgA antibody and ASC levels. However, it is very likely that the small sample size provided insufficient power to adequately estimate the presence and association of anti-LpaB IgA BM cells and seroresponses. Future studies will address this issue by evaluating larger numbers of subjects and vaccine candidates.

Virulent *Shigella* target the M cells that overlie gut-associated lymphoid tissue and rapidly attain an intracellular niche within epithelial cells. SlgA anti-*Shigella* antibodies can prevent mucosal
We thank the volunteers for participating in the clinical trial, the clinical and regulatory staff at the CVD, Drs. William Blackwelder and Yuhuen Wu for helpful statistical discussions, and Dr. S. Crotty for providing PWM. Support for this research was provided by NIH R01-AI057927 (to M.B.S.), U19-AI-082655 (CCHI; to M.B.S.), K23-AI065795 (to J.S.) and N01-AI26461 (VTEU, to M.M.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the NIH.

References


